



Universiteit
Leiden
The Netherlands

Novel insights in MHC class II antigen presentation

Hoorn, B.M. van den

Citation

Hoorn, B. M. van den. (2011, April 6). *Novel insights in MHC class II antigen presentation*. Retrieved from <https://hdl.handle.net/1887/16694>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/16694>

Note: To cite this publication please use the final published version (if applicable).

Chapter 1

Routes to manipulate MHC class II antigen presentation

(In press, Current Opinion in Immunology, 2011)

Routes to manipulate MHC class II antigen presentation

Tineke van den Hoorn*, Petra Paul*, Marlieke L.M. Jongsma* and Jacques Neefjes

Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam NL

* These authors contributed equally. * Correspondence: j.neefjes@nki.nl

Summary

MHC class II molecules (MHC-II) present antigenic fragments acquired in the endocytic route to the immune system for recognition and activation of CD4+ T cells. This ignites a series of immune responses. MHC-II strongly correlates to most autoimmune diseases. Understanding the biology of MHC-II is therefore expected to translate into novel means of autoimmunity control or immune response improvement. Although the basic cell biology of MHC-II antigen presentation is well understood, many novel aspects have been uncovered in recent years including means of antigen delivery, preparation for MHC-II loading, transport processes and vaccination strategies. We will discuss past, present and future of these insights into the biology of MHC-II.

Introduction

Like all glycoprotein's, MHC-II α - and β -chains are synthesized and assembled in the ER. Here they associate with Invariant Chain (Ii), which prevents premature binding of peptides to the MHC-II peptide-binding groove and promotes exit from the ER and transport through the Golgi. The Ii contains a dileucine-based motif recognized by Adaptor Protein 2 (AP2) or AP3 complexes (Dugast et al., 2005; Gupta et al., 2006; McCormick et al., 2005). This motif is required for sorting at the Trans-Golgi-Network (TGN) and plasma membrane (PM) towards the MHC-II containing compartments (MIIC) (Neefjes et al., 1990; Peters et al., 1991; Roche and Cresswell, 1990) (pathway components discussed in this review are summarized in Figure 1). In the MIIC, residing proteases degrade antigens and Ii with the exception of a small fragment (called CLIP), protected by its embedding in the peptide-binding-groove of MHC-II. The CLIP fragment is exchanged for new (antigenic) peptides catalyzed by a unique and dedicated chaperone DM (H2-M in mice, HLA-DM in humans). DM is a MHC-II look-alike that interacts with MHC-II, stabilizing it in a state devoid of peptides, which would otherwise be prone to aggregation and degradation (Kropshofer et al., 1996). The peptide exchange reaction is stimulated by acidic pH and occurs in subdomains of the MIIC (Zwart et al., 2005).

Probably, the MIIC does not have a 'Quality Control System' like the ER that allows exit of properly folded and assembled proteins only. The expression of MHC-II/CLIP complexes at the PM in the absence of DM illustrates this point. The MIIC moves to the PM for surface deposition of MHC-II, most likely after a certain intracellular residency time. In addition, MHC-II-bearing exosomes might




Figure 1: The transport route of MHC class II

After Ii binding in the ER, MHC-II is transported to the MIIC either directly (A) or via the PM (B) due to a dileucine motif in the associated Ii. In the MIIC, the Ii is degraded and the remaining CLIP fragment is exchanged for a new peptide in a process chaperoned by DM. After loading MHC-II is transported to the PM (C) or secreted on exosomes (D). MHC-II, MHC class II molecule; Ii, invariant chain; AP2, Adaptor Protein 2; GILT, gamma-interferon-inducible lysosomal thiol reductase precursor; DM, HLA-DM; DO, HLA-DO; ESCRT, Endosomal Sorting Complex Required for Transport; ATG, Autophagy related; ORP1L, oxysterol-binding protein; RILP, Rab7-interacting lysosomal protein; SLP4, synaptotagmin-like protein 4; EE, early endosome; and MIIC, MHC-II containing compartment.

be released conveying immunological information beyond the initial antigen presenting cell (APC).

The biology of antigen presentation by MHC-II has been studied for over 20 years by many groups and has yielded a fairly consistent view on the molecular basis underlying the successful acquisition of peptide fragments in the endocytic pathway for presentation at the PM. In general terms, assembly of MHC-II, their preparation for peptide loading, the generation of peptide fragments and transport processes are understood at almost atomic resolution. Yet many new findings complicate the initially simple biology. We will describe the state-of-art understanding based on recent insights. We will follow the general route of MHC-II from its birth in the endoplasmic reticulum (ER), through the endosomal pathway to the PM, exosomes and to their degradation. Along this path, we will not only describe new biological findings but also their application as new tools to manipulate MHC-II antigen presentation.

Delivery of Antigens to MHC

Uptake of exogenous antigens can occur via several routes, reviewed by (Burgdorf and Kurts, 2008). Each immune cell type has found its own one. B cells are poorly phagocytic, but they can take up IgM-coated *Salmonella* in a B cell receptor (BCR)-mediated pathway for antigen presentation in context of MHC-II (Souwer et al., 2009). The effectiveness of antigen presentation in dendritic cells (DC) depends on the cells' origin, maturation-stimulus and route of antigen uptake. These observations aid the understanding of immune response initiation and designing of vaccination strategies using DC and activated monocytes (Kamphorst et al., 2010).

Recently it has been shown that DC continue to accumulate antigens via DEC205-mediated endocytosis and Fc γ R-mediated phagocytosis even after maturation, the latter involving the PIP5K isoforms α and γ (Mao et al., 2009). Freshly synthesized or recycled MHC-II is loaded with the newly acquired antigens (Platt et al., 2010). Endocytosis of DEC205 antibody-coupled peptides results in efficient uptake and delivery to the MHC. This strategy has been applied to DC of melanoma patients resulting in effective peptide presentation. The stimulatory capacity of those DC was maintained after cryopreservation, which makes it an interesting approach for cancer immune therapy (Birkholz et al., 2010). Antigen acquisition targeting Ig, Fc, complement or lectin receptors appears to be a feasible strategy to improve MHC-II antigen presentation and immune response outcome.

How cytosolic antigens reach MHC-II and why, although abundant, they only represent a minor fraction of all presented peptides (MHC ligand database; URL: <http://www.syfpeithi.de>) (Rammensee et al., 1999), was unclear for a long time. Autophagy is a cell biological solution for the entry of cytosolic material into the lysosome. Membranes form and encapsulate parts of the cytosol forming autophagosomes, a process requiring ATG5 (Mizushima et al., 2001). As reviewed by Nedjic and colleagues, cortical thymic epithelial cells contain many autophagosomes (Nedjic et al., 2009) generating an array of different peptides, thereby shaping the self-tolerant T cell repertoire, as became clear from studies in ATG5 $^{-/-}$ thymi (Nedjic et al., 2008). ATG5 $^{-/-}$ DCs are defective in phagosome-to-lysosome fusion, thereby inhibiting processing and presentation of extracellular microbial antigens (Lee et al., 2010). Particular proteins are more selectively targeted to the autophagosome when coupled to ATG8/LC3, which in turn enhances their MHC-II presentation rate (Gannage and Munz, 2009).

Antigen processing in the MHC

Antigens have to be unfolded for efficient degradation and peptide formation. One recently identified endosomal protein (called GILT) oxidizes disulfide linkages found in many extracellular proteins (Singh and Cresswell, 2010) and is essential for the presentation of a series of antigens (Arunachalam et al., 2000). GILT activity can strongly enhance antigen presentation of a melanoma antigen (Rausch et al., 2010). Acidic pH and chaperones might participate in further unfolding before substrates are processed by resident proteases. Many of these are cysteine proteases of the cathepsin family and are involved in inflammation, autoimmunity and cancer (reviewed by (Chapman, 2006) and (Conus and Simon, 2010)). Nowadays, various cathepsin inhibitors are tested in primary immune

Table1: Recently developed cathepsin inhibitors and their effects

INHIBITOR	TARGET	EFFECT
ZRLR	Cathepsin B	Enhances presentation of Tetanus Toxin-C (TTC) fragment to T-cells (Reich et al., 2009b).
CatG inhibitor	Cathepsin G	Reduces processing of TTC and Hemagglutinin (HA) peptides and their presentation to CD4+ T-cells (Reich et al., 2009a).
Suc-VPF	Cathepsin G	Reduces processing of TTC and Hemagglutinin (HA) peptides and their presentation to CD4+ T-cells (Reich et al., 2009a)
Compound 47	Cathepsin S	Inhibits processing of invariant chain (Cai et al., 2010a; Cai et al., 2010b)
CAA0225	Cathepsin L	Involved in degradation of autophagosomal membrane markers (Takahashi et al., 2009)

cells as tools for immune response modulation in autoimmune diseases (Table 1).

Manipulating peptide loading of MHC-II in the MIIC

DM can stably associate with a unique co-chaperone DO (H2-O in mice, HLA-DO in humans), which is fairly selectively expressed in immature B cells and certain DC types. DO is also an MHC-II look-alike and functions as a pH sensor that alters the pH optimum of DM-mediated peptide loading of MHC-II to more acidic conditions and thereby changes the peptide repertoire presented by MHC-II (van Ham et al., 2000). In fact, presentation of many peptides is prevented by DO yielding more MHC-II/CLIP expression at the PM. Consequently, T cell help for B cells is reduced when DO is expressed (Draghi and Denzin, 2010). DO may skew the DM support of MHC-II peptide loading to late and more acidic endosomes, which are preferentially accessed by antigens taken up by BCR-mediated endocytosis. It is believed that this is preventing autoimmune responses by controlling the activation of B cells present peptides corresponding to antigens taken up by the BCR (van Ham et al., 2000). Indeed, NOD mice (susceptible to develop Type 1 Diabetes) overexpressing DO present an altered self-peptide repertoire which prevents activation of diabetogenic T cells and hence diabetes onset. DO possibly shapes the overall MHC-II self-peptide repertoire to improve T cell tolerance (Yi et al., 2010).

Small molecules affecting peptide loading of MHC-II can be of interest for autoimmunity (inhibitors) or vaccines (accelerators). Amines like chloroquine are known to neutralize MIIC and inhibit peptide loading (Ziegler and Unanue, 1982). Protease inhibitors affect the degradation of Ii or antigen (Table1). More recently, a family of compounds was described to accelerate MHC-II peptide loading *in vitro*, without the help of DM, and promote peptide binding in APC *in vivo* (Call et al., 2009). Altered Peptide Ligands (APLs) are built to be more protease resistant, to reach the MIIC more easily and to be presented more efficiently (for review (Burster and Boehm, 2010)). Manipulating MHC-II function becomes a realistic option to direct immune responses.

A topological problem: retrofusion or exosomes?

MIIC consist of a limiting (outer) membrane and intraluminal vesicles (ILV). It is still under debate whether ILV are a stable structure or dynamically form and disappear again through retrofusion with the limiting membrane. The subdomains of MIIC differ. The ILV contains tetraspanin molecules, cholesterol and the lipid LBPA, while the limiting membrane concentrates molecules like the GTPase RAB7, LAMP and the cholesterol transporter ABCA1. MHC-II and DM are detected on both membranes. Studies have shown that the ILV are their preferred site of interaction (Zwart et al., 2005). MHC-II/DM complexes might be stabilized through association with the tetraspanin web (made of CD63, CD82 and others) (Hammond et al., 1998; Escola et al., 1996). The interaction of MHC-II and DM on ILV has interesting consequences for pathogens in phagosomes, such as *Salmonella*. Phagosomes do not have ILV and MHC-II located at their limiting membrane fails to acquire peptides due to lack of DM support, therefore allowing immune escape of intracellular bacteria (Zwart et al., 2005).

The ILV can be secreted to the extracellular environment as exosomes. Mass spectrometry analysis of protein and lipid content of purified B cell exosomes verifies their origin from ILV of MIIC (albeit at a considerably higher resolution) (Wubbolts et al., 2003; Buschow et al., 2010). The turn-over of MIIC takes only hours, whereas the half-life of MHC-II (8-48 hours) (Koppelman et al., 1997) or CD63 (2 days) (Engering et al., 2003) is considerably longer implying that the proteins have to be recovered from the ILV not to be lost through exosome secretion. To our opinion, exosomes are the result of inefficient retrofusion of the ILV to the limiting membrane of MIIC before fusion with the PM. How the process of retrofusion occurs is unclear. Alternatively ILV might be stable nanocomplexes that survive necrosis, like proteasome and ribosome, which can be easily detected in tissue culture medium and body fluids (Deutsch et al., 2005). Nonetheless, exosomes can have interesting functions.


Function and Application of MHC-II-bearing Exosomes

Exosomes are shed by almost all cell types and differ in content accordingly (reviewed in (Simpson et al., 2009)). Exosomes contain cytosol. How the cytosolic contents are selected, is unknown. Exosomes resemble their cell of origin's topology and expose proteins like MHC class I and II, CD1, tetraspanins, costimulatory molecules and adhesion molecules, such as ICAM-1. In fact, MHC-II-bearing exosomes can be considered 'nano immune cells' and have been found to exert both immune stimulatory and regulatory functions in intercellular communication (Figure 2). When shed by DC, exosomes can present antigen in context of MHC-II to activated T cells or T cell lines directly (Arnold and Mannie, 1999) or indirectly to naïve T cells when recaptured by recipient APCs (Thery et al., 2002). Such recapture requires binding to host membranes mediated by LFA-1 and its ligand ICAM-1 on the exosome (Nolte-'t Hoen et al., 2009; Segura et al., 2007). Tumours are known to shed exosomes. Szajnik et al. have recently defined a new escape mechanism in cancer based on the activation of regulatory T cells (Tregs) in tumour patients (Szajnik et al., 2010). Whether exosomes enter the recipient cells' MIIC for retrofusion, fuse with the PM or act as 'nano immune cells' is a fascinating subject and still unclear.

Immune Activation

Dendritic Cell

T Helper Cell



Immune Inhibition

Tumor Cell

Regulatory T Cell




Figure 2: Exosome functions

Exosomes derived from dendritic cells can exert immune activating functions. Naïve T cells can be primed in an antigen-specific manner. Exosomes derived from tumour cells can exhibit immune regulatory functions by activating regulatory T cells. ICAM-1, intercellular adhesion molecule 1; LFA-1, lymphocyte function-associated antigen 1; TCR, T cell receptor; IL-10, interleukin-10; TGFb, tumour growth factor β ; and TAA, tumour associated antigen

The immunogenetic potential of DC-derived exosomes has been demonstrated for vaccines against *Leishmania major* (Schnitzer et al., 2010) and as cancer therapies *in vivo* in the past (reviewed in (Thery et al., 2009)). An alternative to the isolation of exosomes from patient-derived DCs might be the generation of artificial exosomes (De La Pena et al., 2009). The advantage of exosome-based vaccines over other vaccination strategies remains to be proven in side-by-side comparative studies.

And out we go... MHC-II transport to the plasma membrane

MHC-II is transported from the MIIC to the PM along microtubules in at least two


different ways: (1) MIIC can move to the PM followed by fusion of the limiting membrane with the PM (Wubbolts et al., 1999) (2) Tubules extend from MIIC towards the PM (Boes et al., 2003; Chow et al., 2002), and vesicles may bud off to fuse with the PM (Kleijmeer et al., 2001). This has been detected mainly in activated DC and not in other cell types. Close inspection of both routes shows that MIIC move in a bidirectional and stop-and-go manner by the activities of the dynein and kinesin motor proteins. Cholesterol, shown to influence MHC-II PM expression (Kuipers et al., 2005), controls the RAB7 effector ORP1L that controls RILP and the dynein motor. High cholesterol prevents the release of the dynein motor, inhibiting MIIC delivery to the PM (Rocha et al., 2009). How movement to the PM by kinesin motors is controlled, is unclear. Finally, MIIC have to fuse to the PM which probably requires the activity of RAB27A and its effector SLP4. This is directly correlated to the secretion of exosomes in HeLa cells (Ostrowski et al., 2010). Sorting of MHC-II to exosomes was shown to be ubiquitination-independent. Forced ubiquitination of MHC-II induces a decrease of MHC-II at the PM, but no enrichment on exosomes (Gauvreau et al., 2009). In the study of Buschow et al. it was shown that coculturing of DC with cognate T cells induced DC activation and exosome secretion independent of ubiquitination (Buschow et al., 2009). Although parts of MHC-II transport control are understood in detail, regulation of most other steps remains obscure and may be uncovered in the coming years.

Finally at the PM; internalization and recycling

It has been known for some time that the half-life of MHC-II at the PM is cell type dependent. When MHC-II associated to Ii arrives at the PM, they are internalized because of the dileucine motif in the Ii (Simonsen et al., 1998). MHC-II, devoid of Ii, does not contain such internalization motifs and remains at the PM. Still, MHC-II has a longer lifespan on B cells than on monocytes, which is even further reduced following IL-10 exposure (Koppelman et al., 1997). IL-10 upregulates a ubiquitin ligase called MARCH1, which modifies MHC-II and reduces its half-life (Thibodeau et al., 2008). The downregulation of MARCH1 expression in mature DC compared to immature DC corresponds to an increase in MHC-II half-life at the PM of the former (de Gassart et al., 2008) (Figure 3). Viruses and bacteria can use the ubiquitination machinery to manipulate MHC expression (Nathan and Lehner, 2009). *Salmonella typhimurium* inhibits PM expression of MHC-II in DCs by ubiquitinating the HLA-DR β chain using bacterial type III secretion system effectors rather than MARCH1 to directly modify HLA-DR β (Mitchell et al., 2004; Cheminay et al., 2005; Lapaque et al., 2009). HIV-Nef affects MHC-II expression and peptide loading by a different mechanism. The Nef protein triggers MHC-II internalization in a cholesterol dependent and clathrin- and dynamin-independent manner (Chaudhry et al., 2009), but the exact details are unknown.

Upon internalization MHC-II has two options: (1) return to the PM prior to or after peptide exchange or (2) become degraded. In recycling endosomes, MHC-II can be loaded with new peptides in a DM-dependent (Pathak et al., 2001) or independent manner (Sinnathamby and Eisenlohr, 2003) and transported back to the PM. This process involves at least ARF6, RAB35 and EHD1 (Walseng et al., 2008). Uptake of antigens in early endosomal compartments (that are relatively

Immature DC



Mature DC




Figure 3: MHC class II internalization, recycling and degradation

At the PM of immature DC, MHC-II can be ubiquitinated by MARCH1 and is transported via ARF6/RAB35/EHD1-positive tubular structures towards Recycling Endosomes (RE).

poor in proteases (Fernandez-Borja et al., 1996)) will allow presentation of other peptides than those generated in MIIC, hence broadening the peptide repertoire for the good or bad, which is unpredictable. Where MHC-II ends-up, when recycling fails, remains unclear. The reductase GILT (breaking disulfide bonds in the Ig domains of MHC-II) and cathepsins, such as cathepsin G, which degrades the MHC-II β -chain *in vitro* (Burstner et al., 2010), might be involved. The question how the life of MHC-II is exactly terminated, however, remains open. Clearly, MHC-II is a cannibal presenting fragments of its deceased brothers or sisters. In fact, such MHC-II derived peptides are major constituents of the MHC-II peptide repertoire.

Conclusion

The cell biology of MHC-II has been studied for over two decades starting with the work of Unanue et al., who demonstrated inhibition of antigen presentation by chloroquine (Ziegler and Unanue, 1982). Since then many steps have been solved at the cell biological and atomic level. MHC-II antigen presentation comprises of processes like transport via various endosomal compartments, synthesis, ubiquitination and degradation. The routes of MHC-II involve many targets for manipulation to affect MHC-II expression and peptide loading, which is relevant for disease states like autoimmunity, infection and cancer.

Acknowledgements

This work was supported by grants of NWO-ALW and CW and an ERC program grant.

References

- Arnold,P.Y. and Mannie,M.D. (1999). Vesicles bearing MHC class II molecules mediate transfer of antigen from antigen-presenting cells to CD4+ T cells. *Eur J Immunol* 29, 1363-1373.
- Arunachalam,B., Phan,U.T., Geuze,H.J., and Cresswell,P. (2000). Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). *Proc Natl Acad Sci U S A* 97, 745-750.
- Birkholz,K., Schwenkert,M., Kellner,C., Gross,S., Fey,G., Schuler-Thurner,B., Schuler,G., Schaft,N., and Dorrie,J. (2010). Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. *Blood* 116, 2277-2285.
- Endocytosis receptor DEC205 can deliver helper-epitopes to human monocyte-derived DC when coupled to an anti-DEC205 antibody. This results in effective MHC-II restricted antigen presentation in DC. This is a promising strategy for antigen-delivery for the immune therapy of various diseases.
- Boes,M., Bertho,N., Cerny,J., Op den Brouw,M., Kirchhausen,T., and Ploegh,H. (2003). T cells induce extended class II MHC compartments in dendritic cells in a Toll-like receptor-dependent manner. *J Immunol* 171, 4081-4088.
- Burgdorf,S. and Kurts,C. (2008). Endocytosis mechanisms and the cell biology of antigen presentation. *Curr. Opin. Immunol.* 20, 89-95.
- Burster,T. and Boehm,B.O. (2010). Processing and presentation of (pro)-insulin in the MHC class II pathway: the generation of antigen-based immunomodulators in the context of type 1 diabetes mellitus. *Diabetes Metab Res Rev* 26, 227-238.
- Burster,T., Macmillan,H., Hou,T., Schilling,J., Truong,P., Boehm,B.O., Zou,F., Lau,K., Strohmaier,M., Schaffert,S., Busch,R., and Mellins,E.D. (2010). Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules. *Immunology* 130, 436-446.
- Buschow,S.I., Nolte-t Hoen,E.N., van Niel,G., Pols,M.S., ten Broeke,T., Lauwen,M., Ossendorp,F., Melief,C.J., Raposo,G., Wubbolts,R., Wauben,M.H., and Stoorvogel,W. (2009). MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. *Traffic* 10, 1528-1542.
- This study demonstrates that upon coculturing of a T cell line with DC the number of exosomes secreted by the DC increases along with the levels of MHC-II on the microvesicles. By using a mutant MHC-II molecule that cannot be ubiquitinated, they demonstrate that the transfer of MHC-II to exosomes is independent of ubiquitination.
- Buschow,S.I., van Balkom,B.W., Aalberts,M., Heck,A.J., Wauben,M., and Stoorvogel,W. (2010). MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis. *Immunol Cell Biol.*
- Cai,J., Baugh,M., Black,D., Long,C., Jonathan Bennett,D., Dempster,M., Fradera,X., Gillespie,J., Andrews,F., Boucharens,S., Bruin,J., Cameron,K.S., Cumming,I., Hamilton,W., Jones,P.S., Kaptein,A., Kinghorn,E., Maidment,M., Martin,I., Mitchell,A., Rankovic,Z., Robinson,J., Scullion,P., Uitdehaag,J.C., Vink,P., Westwood,P., van Zeeland,M., van Berkum,L., Bastiani,M., and Meulemans,T. (2010a). 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors. *Bioorg Med Chem Lett* 20, 4350-4354.
- Cai,J., Bennett,D.J., Rankovic,Z., Dempster,M., Fradera,X., Gillespie,J., Cumming,I., Finlay,W., Baugh,M., Boucharens,S., Bruin,J., Cameron,K.S., Hamilton,W., Kerr,J., Kinghorn,E., McGarry,G., Robinson,J., Scullion,P., Uitdehaag,J.C., van Zeeland,M., Potin,D., Sanieri,L., Fouquet,A., Chevallier,F., Deronzier,H., Dorleans,C., and Nicolai,E. (2010b). 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. *Bioorg Med Chem Lett* 20, 4447-4450.

Chapter 1

Call,M.J., Xing,X., Cuny,G.D., Seth,N.P., Altmann,D.M., Fugger,L., Krogsgaard,M., Stein,R.L., and Wucherpfennig,K.W. (2009). In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. *J Immunol* 182, 6342-6352.

Chapman,H.A. (2006). Endosomal proteases in antigen presentation. *Curr Opin Immunol* 18, 78-84.

Chaudhry,A., Verghese,D.A., Das,S.R., Jameel,S., George,A., Bal,V., Mayor,S., and Rath,S. (2009). HIV-1 Nef promotes endocytosis of cell surface MHC class II molecules via a constitutive pathway. *J Immunol* 183, 2415-2424.

- This study demonstrates the role of HIV-1Nef in delaying MHC-II transport to the PM in monocytes. At the same time the rate of MHC-II removal from the cell surface is increased. The data in this paper suggest that Nef activates the normal MHC-II endocytosis route to reduce MHC-II antigen presentation.

Cheminay,C., Mohlenbrink,A., and Hensel,M. (2005). Intracellular Salmonella inhibit antigen presentation by dendritic cells. *J Immunol* 174, 2892-2899.

Chow,A., Toomre,D., Garrett,W., and Mellman,I. (2002). Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. *Nature* 418, 988-994.

Conus,S. and Simon,H.U. (2010). Cathepsins and their involvement in immune responses. *Swiss Med Wkly* 140, w13042.

- This review summarizes the role of cathepsins in innate and adaptive immunity. Furthermore, the involvement of cathepsins in the pathogenesis of (autoimmune) diseases is discussed.

de Gassart,A., Camosseto,V., Thibodeau,J., Ceppi,M., Catalan,N., Pierre,P., and Gatti,E. (2008). MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. *Proc Natl Acad Sci U S A* 105, 3491-3496.

De La Pena,H., Madrigal,J.A., Rusakiewicz,S., Bencsik,M., Cave,G.W., Selman,A., Rees,R.C., Travers,P.J., and Dodi,I.A. (2009). Artificial exosomes as tools for basic and clinical immunology. *J Immunol Methods* 344, 121-132.

Deutsch,E.W., Eng,J.K., Zhang,H., King,N.L., Nesvizhskii,A.I., Lin,B., Lee,H.,

Yi,E.C., Ossola,R., and Aebersold,R. (2005). Human Plasma PeptideAtlas. *Proteomics* 5, 3497-3500.

Draghi,N.A. and Denzin,L.K. (2010). H2-O, a MHC class II-like protein, sets a threshold for B-cell entry into germinal centers. *Proc Natl Acad Sci U S A* 107, 16607-16612.

Dugast,M., Toussaint,H., Dousset,C., and Benaroch,P. (2005). AP2 clathrin adaptor complex, but not AP1, controls the access of the major histocompatibility complex (MHC) class II to endosomes. *J Biol Chem* 280, 19656-19664.

Engering,A., Kuhn,L., Fluitsma,D., Hoefsmit,E., and Pieters,J. (2003). Differential post-translational modification of CD63 molecules during maturation of human dendritic cells. *Eur J Biochem* 270, 2412-2420.

Escola,J.M., Deleuil,F., Stang,E., Boretto,J., Chavrier,P., and Gorvel,J.P. (1996). Characterization of a lysozyme-major histocompatibility complex class II molecule-loading compartment as a specialized recycling endosome in murine B lymphocytes. *J Biol Chem* 271, 27360-27365.

Fernandez-Borja,M., Verwoerd,D., Sanderson,F., Aerts,H., Trowsdale,J., Tulp,A., and Neefjes,J. (1996). HLA-DM and MHC class II molecules co-distribute with peptidase-containing lysosomal subcompartments. *Int Immunol* 8, 625-640.

Gannage,M. and Munz,C. (2009). Monitoring macroautophagy by major histocompatibility complex class II presentation of targeted antigens. *Methods Enzymol* 452, 403-421.

Routes to manipulate MHC Class II antigen presentation

Gauvreau,M.E., Cote,M.H., Bourgeois-Daigneault,M.C., Rivard,L.D., Xiu,F., Brunet,A., Shaw,A., Steimle,V., and Thibodeau,J. (2009). Sorting of MHC class II molecules into exosomes through a ubiquitin-independent pathway. *Traffic* 10, 1518-1527.

Gupta,S.N., Kloster,M.M., Rodionov,D.G., and Bakke,O. (2006). Re-routing of the invariant chain to the direct sorting pathway by introduction of an AP3-binding motif from LIMP II. *Eur J Cell Biol* 85, 457-467.

Hammond,C., Denzin,L.K., Pan,M., Griffith,J.M., Geuze,H.J., and Cresswell,P. (1998). The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. *J Immunol* 161, 3282-3291.

Kamphorst,A.O., Guernonprez,P., Dudziak,D., and Nussenzweig,M.C. (2010). Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. *J Immunol* 185, 3426-3435.

●● An extensive and thorough investigation of antigen processing and presentation capacities of differentially activated APC is presented here. The influence of various maturation stimuli on MHC-I and MHC-II antigen presentation is shown *in vivo*.

Kleijmeer,M., Ramm,G., Schuurhuis,D., Griffith,J., Rescigno,M., Ricciardi-Castagnoli,P., Rudensky,A.Y., Ossendorp,F., Melief,C.J., Stoorvogel,W., and Geuze,H.J. (2001). Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. *J Cell Biol* 155, 53-63.

Koppelman,B., Neefjes,J.J., de Vries,J.E., and Waal Malefyt,R. (1997). Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. *Immunity* 7, 861-871.

Kropshofer,H., Vogt,A.B., Moldenhauer,G., Hammer,J., Blum,J.S., and Hammerling,G.J. (1996). Editing of the HLA-DR-peptide repertoire by HLA-DM. *EMBO J* 15, 6144-6154.

Kuipers,H.F., Biesta,P.J., Groothuis,T.A., Neefjes,J.J., Mommaas,A.M., and van den Elsen,P.J. (2005). Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. *Hum. Immunol.* 66, 653-665.

Lapaque,N., Jahnke,M., Trowsdale,J., and Kelly,A.P. (2009). The HLA-DRAalpha chain is modified by polyubiquitination. *J Biol Chem* 284, 7007-7016.

Lee,H.K., Mattei,L.M., Steinberg,B.E., Alberts,P., Lee,Y.H., Chervonsky,A., Mizushima,N., Grinstein,S., and Iwasaki,A. (2010). In vivo requirement for Atg5 in antigen presentation by dendritic cells. *Immunity* 32, 227-239.

● In mice, ATG5^{-/-} DC are impaired in priming CD4⁺ T cells after Herpes Simplex virus infection. ATG5 not only functions in processing cytosolic antigens, but is also required for the processing and subsequent presentation of MHC-II peptides derived from phagocytosed microbial antigens.

Mao,Y.S., Yamaga,M., Zhu,X., Wei,Y., Sun,H.Q., Wang,J., Yun,M., Wang,Y., Di Paolo,G., Bennett,M., Mellman,I., Abrams,C.S., De Camilli,P., Lu,C.Y., and Yin,H.L. (2009). Essential and unique roles of PIP5K-gamma and -alpha in Fcgamma receptor-mediated phagocytosis. *J Cell Biol* 184, 281-296.

McCormick,P.J., Martina,J.A., and Bonifacio,J.S. (2005). Involvement of clathrin and AP-2 in the trafficking of MHC class II molecules to antigen-processing compartments. *Proc Natl Acad Sci U S A* 102, 7910-7915.

Mitchell,E.K., Mastroeni,P., Kelly,A.P., and Trowsdale,J. (2004). Inhibition of cell surface MHC class II expression by Salmonella. *Eur J Immunol* 34, 2559-2567.

Mizushima,N., Yamamoto,A., Hatano,M., Kobayashi,Y., Kabeya,Y., Suzuki,K., Tokuhisa,T., Ohsumi,Y., and Yoshimori,T. (2001). Dissection of autophagosome formation using Apg5-deficient

Chapter 1

mouse embryonic stem cells. *J Cell Biol* 152, 657-668.

Nathan, J.A. and Lehner, P.J. (2009). The trafficking and regulation of membrane receptors by the RING-CH ubiquitin E3 ligases. *Exp Cell Res* 315, 1593-1600.

Nedjic, J., Aichinger, M., Emmerich, J., Mizushima, N., and Klein, L. (2008). Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. *Nature* 455, 396-400.

- Thymic epithelial cells, displaying MHC ligands for positive T cell selection, contain a high number of autophagosomes. An *in vivo* study of the MHC-II-restricted T cell receptor repertoire in mice with ATG5-deficient thymus revealed that autophagy supports positive T cell selection and tolerance induction.

Nedjic, J., Aichinger, M., Mizushima, N., and Klein, L. (2009). Macroautophagy, endogenous MHC II loading and T cell selection: the benefits of breaking the rules. *Curr Opin Immunol* 21, 92-97.

Neefjes, J.J., Stollorz, V., Peters, P.J., Geuze, H.J., and Ploegh, H.L. (1990). The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route. *Cell* 61, 171-183.

Nolte-'t Hoen, E.N., Buschow, S.I., Anderton, S.M., Stoorvogel, W., and Wauben, M.H. (2009). Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. *Blood* 113, 1977-1981.

Ostrowski, M., Carmo, N.B., Krumeich, S., Fanget, I., Raposo, G., Savina, A., Moita, C.F., Schauer, K., Hume, A.N., Freitas, R.P., Goud, B., Benaroch, P., Hacohen, N., Fukuda, M., Desnos, C., Seabra, M.C., Darchen, F., Amigorena, S., Moita, L.F., and Thery, C. (2010). Rab27a and Rab27b control different steps of the exosome secretion pathway. *Nat Cell Biol* 12, 19-30.

- This paper identifies five RAB proteins that inhibit exosome secretion when silenced in CIITA-expressing HeLa cells without affecting normal protein secretion. The phenotype after silencing two of these RABs (RAB27A and RAB27B) is characterized and effectors are identified.

Pathak, S.S., Lich, J.D., and Blum, J.S. (2001). Cutting edge: editing of recycling class II:peptide complexes by HLA-DM. *J Immunol* 167, 632-635.

Peters, P.J., Neefjes, J.J., Oorschot, V., Ploegh, H.L., and Geuze, H.J. (1991). Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. *Nature* 349, 669-676.

Platt, C.D., Ma, J.K., Chalouni, C., Ebersold, M., Bou-Reslan, H., Carano, R.A., Mellman, I., and Delamarre, L. (2010). Mature dendritic cells use endocytic receptors to capture and present antigens. *Proc Natl Acad Sci U S A* 107, 4287-4292.

- Antigen uptake via DEC205-mediated-endocytosis and FcγR-mediated-phagocytosis remains efficient in mature DC. The acquired antigens are loaded onto a small pool of newly synthesized or recycled MHC-II.

Rammensee, H., Bachmann, J., Emmerich, N.P., Bachor, O.A., and Stevanovic, S. (1999). SYFPEITHI: database for MHC ligands and peptide motifs. *Immunogenetics* 50, 213-219.

Rausch, M.P., Irvine, K.R., Antony, P.A., Restifo, N.P., Cresswell, P., and Hastings, K.T. (2010). GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. *J Immunol* 185, 2828-2835.

Reich, M., Lesner, A., Legowska, A., Sienczyk, M., Oleksyszyn, J., Boehm, B.O., and Burster, T. (2009a). Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells. *Mol Immunol* 46, 2994-2999.

Reich, M., Wiczerzak, E., Jankowska, E., Palesch, D., Boehm, B.O., and Burster, T. (2009b). Specific cathepsin B inhibitor is cell-permeable and activates presentation of TTC in primary human dendritic cells. *Immunol Lett* 123, 155-159.

Rocha, N., Kuijl, C., van der Kant, R., Janssen, L., Houben, D., Janssen, H., Zwart, W., and Neefjes, J.

(2009). Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning. *J Cell Biol* 185, 1209-1225.

Roche,P.A. and Cresswell,P. (1990). Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. *Nature* 345, 615-618.

Schnitzer,J.K., Berzel,S., Fajardo-Moser,M., Remer,K.A., and Moll,H. (2010). Fragments of antigen-loaded dendritic cells (DC) and DC-derived exosomes induce protective immunity against *Leishmania major*. *Vaccine* 28, 5785-5793.

Segura,E., Guerin,C., Hogg,N., Amigorena,S., and Thery,C. (2007). CD8+ dendritic cells use LFA-1 to capture MHC-peptide complexes from exosomes in vivo. *J Immunol* 179, 1489-1496.

Simonsen,A., Bremnes,B., Nordeng,T.W., and Bakke,O. (1998). The leucine-based motif DDQxxLI is recognized both for internalization and basolateral sorting of invariant chain in MDCK cells. *Eur J Cell Biol* 76, 25-32.

Simpson,R.J., Lim,J.W., Moritz,R.L., and Mathivanan,S. (2009). Exosomes: proteomic insights and diagnostic potential. *Expert Rev Proteomics* 6, 267-283.

Singh,R. and Cresswell,P. (2010). Defective cross-presentation of viral antigens in GILT-free mice. *Science* 328, 1394-1398.

Sinnathamby,G. and Eisenlohr,L.C. (2003). Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification. *J Immunol* 170, 3504-3513.

Souwer,Y., Griekspoor,A., Jorritsma,T., de Wit,J., Janssen,H., Neefjes,J., and van Ham,S.M. (2009). B cell receptor-mediated internalization of salmonella: a novel pathway for autonomous B cell activation and antibody production. *J Immunol* 182, 7473-7481.

Szajnik,M., Czystowska,M., Szczepanski,M.J., Mandapathil,M., and Whiteside,T.L. (2010). Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). *PLoS One* 5, e11469.

- This study shows that upon coculture of CD4+ T cells with tumor-derived exosomes Tregs could be generated, which exhibited suppressor functions.

Takahashi,K., Ueno,T., Tanida,I., Minematsu-Ikeguchi,N., Murata,M., and Kominami,E. (2009). Characterization of CAA0225, a novel inhibitor specific for cathepsin L, as a probe for autophagic proteolysis. *Biol Pharm Bull* 32, 475-479.

Thery,C., Duban,L., Segura,E., Veron,P., Lantz,O., and Amigorena,S. (2002). Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. *Nat Immunol* 3, 1156-1162.

- This comprehensive review provides a good overview on the biology of exosomes of all cellular origins. It describes their properties and various functions reported thus far *in vitro* as well as *in vivo*.

Thery,C., Ostrowski,M., and Segura,E. (2009). Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol* 9, 581-593.

Thibodeau,J., Bourgeois-Daigneault,M.C., Huppe,G., Tremblay,J., Aumont,A., Houde,M., Bartee,E., Brunet,A., Gauvreau,M.E., de Gassart,A., Gatti,E., Baril,M., Cloutier,M., Bontron,S., Fruh,K., Lamarre,D., and Steimle,V. (2008). Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. *Eur J Immunol* 38, 1225-1230.

- Immunosuppressant IL-10 reduces MHC-II expression in human monocytes by upregulating the ubiquitin ligase MARCH1.

van Ham,M., van Lith,M., Lillemeier,B., Tjin,E., Gruneberg,U., Rahman,D., Pastoors,L., van Meijgaarden,K., Roucard,C., Trowsdale,J., Ottenhoff,T., Pappin,D., and Neefjes,J. (2000). Modulation of the major histocompatibility complex class II-associated peptide repertoire by human

Chapter 1

histocompatibility leukocyte antigen (HLA)-DO. *J Exp Med* 191, 1127-1136.

Walseng,E., Bakke,O., and Roche,P.A. (2008). Major histocompatibility complex class II-peptide complexes internalize using a clathrin- and dynamin-independent endocytosis pathway. *J Biol Chem* 283, 14717-14727.

Wubbolts,R., Fernandez-Borja,M., Jordens,I., Reits,E., Dusseljee,S., Echeverri,C., Vallee,R.B., and Neefjes,J. (1999). Opposing motor activities of dynein and kinesin determine retention and transport of MHC class II-containing compartments. *J. Cell Sci.* 112 (Pt 6), 785-795.

Wubbolts,R., Leckie,R.S., Veenhuizen,P.T., Schwarzmann,G., Mobius,W., Hoernschemeyer,J., Slot,J.W., Geuze,H.J., and Stoorvogel,W. (2003). Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. *J Biol Chem* 278, 10963-10972.

Yi,W., Seth,N.P., Martillotti,T., Wucherpfennig,K.W., Sant'Angelo,D.B., and Denzin,L.K. (2010). Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence. *J Clin Invest* 120, 1324-1336.

Ziegler,H.K. and Unanue,E.R. (1982). Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. *Proc. Natl. Acad. Sci. U S A* 79, 175-178.

Zwart,W., Griekspoor,A., Kuijl,C., Marsman,M., van Rheenen,J., Janssen,H., Calafat,J., van Ham,M., Janssen,L., van Lith,M., Jalink,K., and Neefjes,J. (2005). Spatial separation of HLA-DM/HLA-DR interactions within MIIIC and phagosome-induced immune escape. *Immunity* 22, 221-233.

